Takeda proposes sale of Shire drug to gain European approval
Share:
(Reuters) - Takeda Pharmaceutical Co Ltd has proposed to European regulators it could sell a Shire treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger. The Japanese drug developer said it had proposed divesting Shire's pipeline compound SHP647, which is currently in Phase III clinical trials, along with some associated rights.It said it did not expect the issue to delay its..